NZ599093B - Detection of bacteria in biological fluids - Google Patents

Abstract

599093 Provided is method of method for detecting bacteria in a biological fluid of animal cells, the method comprising adding (i) a detergent for reducing the respiration of blood cells, and (ii) a bacterial growth promoter; and measuring and/or detecting the level of glucose in the biological fluid over a period of time, wherein a decrease in the level of glucose indicates the presence of bacteria. The cells can be platelets and the detergent can be SPS. id over a period of time, wherein a decrease in the level of glucose indicates the presence of bacteria. The cells can be platelets and the detergent can be SPS.

Description

NEW ZEALAND PATENTS ACT, 1953 COMPLETE SPECIFICATION DETECTION OF BACTERIA IN BIOLOGICAL FLUIDS We, PALL CORPORATION, a corporation of the State ofNew York, United States of America, of 25 Harbor Park Drive, Port Washington, New York 11050, United States of America, do hereby e the invention for which we pray that a patent may be granted to us, and the method by which it is to be med, to be particularly described in and by the following statement: DETECTION OF BACTERIA IN BIOLOGICAL FLUIDS BACKGROUND OF THE INVENTION Blood is conventionally processed, e.g., separated into ents, to provide a variety ofvaluable products such as transfusion products. Blood components or products such as buffy coat and platelets may be pooled during processing, e.g., 4-6 units of platelet concentrate can be pooled before administration as a transfusion product. onally, blood components processed in a closed system (e.g., without exposing the components to the outside environment) can be stored before administration. For example, red blood cells can be stored for several weeks, and platelets can be stored for several days (e.g., 5 days according to current U.S. practice).

Stored and/or non-stored components can include undesirable al such as bacteria. Bacteria can contaminate the blood or blood component during blood collection (including blood sampling) and/or e. One source ofbacterial contamination may be the blood s skin, which may contain one or more varieties of bacteria. Since swabbing the donor's skin (e.g., with alcohol) prior to venipuncture may be inadequate to assure ity, the bacteria may pass into the blood collection container, and the bacteria may reproduce while the blood or blood component is stored. Additionally, phlebotomy needles may cut a disc of skin when the phlebotomy needle is inserted into the donor, allowing the bacteria-containing skin plug to pass with the blood into the blood collection container.

Other sources of contamination e the donor‘s blood, the environment (including the air, and the equipment in the environment), and the tomist.

Contamination can occur while the unit ofblood is being donated and/or while samples of blood are being obtained.

Since some blood components (e.g., ets) are typically stored at ambient temperatures, the m of contamination may be magnified, as many species ofbacteria reproduce more rapidly at ambient temperatures.

Contaminated blood products, especially bacterially contaminated blood products, pose a potential health risk to those who come into t with, or receive, these products.

For example, the administration of transfusion ts with bacterial contamination can have adverse affects on the recipient, and the administration of platelets with e levels ofbacterial contamination is ated in a number of cases of severe morbidity or death each year in the U.S.

Some existing techniques for detecting bacteria are labor- and time-intensive and may require expensive equipment. Some ofthe techniques may allow limited sampling, provide inaccurate results, and/0r fail to detect certain species of bacteria. Additionally, the techniques may introduce contamination from the environment into the s.

It is an object of the present invention to provide for ameliorating at least some of the disadvantages ofthe prior art; and/or to provide the public with a useful choice. These and other advantages ofthe t invention will be apparent fiom the description as set forth below.

BRIEF SUMMARY OF THE INVENTION In a first embodiment, the invention provides a method for detecting bacteria in ical fluids such as blood and blood products, the method comprising placing a biological fluid ly containing bacteria in contact with a detergent for reducing the respiration ofblood cells, and a bacterial growth promoter, and measuring and/or detecting, over a period of time, the level of glucose in a container containing the biological fluid, the ent, and the bacterial growth promoter.

In a second embodiment ofthe invention provides a system for detecting bacteria in biological fluids such as blood and blood products when used in the method ofthe invention, the system comprising a glucose reading and/or measuring device, and a biological fluid sampling device comprising a container suitable for g a biological fluid, the container comprising an access port, and ning a detergent for ng the respiration ofblood cells, and a ial growth promoter.

Since the respiration of the blood cells (that use glucose as a substrate for their metabolism) is d in the presence ofthe detergent, and since bacteria utilize glucose during their metabolic cycles (aerobic bacteria utilize glucose during glycolysis, anaerobic bacteria utilize glucose during fermentation), if bacteria are present in the biological fluid, ial growth will be promoted in the presence ofthe growth promoter, and the level of glucose will decrease over time. Thus, change in the level ofglucose is used as a surrogate marker for bacterial detection.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S) Figure 1 shows an embodiment of a bacteria detection system ing to the invention, comprising a biological fluid sampling device comprising a ner suitable for g a biological fluid, the container comprising a glucose sampling port, and containing a detergent for reducing the respiration ofblood cells, and a bacterial growth promoter, and a glucose reading and/or glucose measuring device.

Figure 2 shows another embodiment of a bacteria detection system according to the ion, comprising a glucose reading and/or glucose measuring , and a biological fluid processing system, comprising a plurality of biological fluid containers, and a biological sampling device as shown in Figure 1.

Figure 3 shows another embodiment of a bacteria detection system according to the ion, comprising a glucose reading and/0r e measuring device, and a biological fluid processing system, sing a plurality of biological fluid containers, a vent, a leukocyte depletion filter, a vent pouch, and a biological sampling device as shown in Figure 1.

ED DESCRIPTION OF THE INVENTION Advantageously, the invention not only allows detection of aerobic bacteria, but also detection of obligate bic bacteria, and detection of facultative anaerobic bacteria not using oxygen for their metabolism.

In an embodiment, a method for detecting bacteria in ical fluid is provided, the method comprising (a) placing a biological fluid, the biological fluid possibly containing bacteria, in a container, the container including (i) a detergent for reducing the respiration of blood cells, and (ii) a bacterial growth er; and, (b) measuring and/or detecting the level ofglucose in the biological fluid in the container over a period of time, wherein a decrease in the level of glucose over the period oftime indicates the presence ofbacteria.

Embodiments ofthe method comprise measuring and/or detecting a first level of glucose in the container, and, within about 4 to about 15 hours ofmeasuring and/or detecting the first level, measuring and/or detecting a second level of glucose in the ner, or comprise continuously measuring and/or detecting the level ofgluco se in the PC in the container over a period of time.

In an embodiment, processed biological fluid is placed in the container within about 24 hours or less of originally obtaining biological fluid from a t.

Alternatively, or onally, an embodiment of the method comprises collecting a biological fluid from a subject, and, within about 24 hours or less of collecting the biological fluid, passing a portion of ical fluid into the container where the portion of biological fluid is placed in contact with the detergent, and the bacterial growth promoter, and, after a suitable period of time, measuring and/or ing the level of glucose in the container over a period of time. Illustratively, a unit ofblood can be collected, and processed to separate the blood into one or more components, including, for example, PC. Within about 24 hours of collecting the blood, a portion of parated PC can be passed into the container where the portion ofPC is placed in contact with the ent and the bacterial growth promoter, and, after a suitable period of time, measuring and/or detecting the level of glucose in the container over a period of time.

Embodiments ofthe method can include placing the detergent and the bacterial growth promoter in the ner before placing the biological fluid in the container, e. g., the method can se placing the biological fluid in a sampling device ner, the container comprising a glucose sampling port, and containing a detergent for reducing the respiration ofblood cells, and a bacterial growth promoter.

In preferred embodiments, the biological fluid comprises a platelet-containing fluid, such as platelet-rich-plasma, or platelet concentrate; a red blood cell containing fluid, such as whole blood or packed red blood cells; cord blood, stem cell-containing fluid, or a cell e. In some embodiments, the biological fluid comprises a yte-depleted fluid.

In another embodiment, a system for detecting bacteria in biological fluid when used in the method ofthe invention is provided, comprising (a) a biological fluid sampling device comprising a container suitable for containing a biological fluid, the container comprising an access port (preferably, a glucose sampling port), the container containing (i) an effective amount of a detergent for reducing the respiration d cells, and (ii) an effective amount of a bacterial growth promoter; the system further comprising (b) a e reading device and/or a glucose measuring device, the device further comprising a glucose sampling device (such as, for example, a t pad and/or a test strip), wherein the reading and/or measuring device is suitable for, over a period oftime, measuring and/or detecting a first level of glucose in the biological fluid, and a second level ofglucose in the biological fluid, wherein a decrease in the level of glucose over the period oftime indicates the presence ofbacteria.

Typically, the biological fluid sampling device container suitable for containing the biological fluid is a flexible container.

In a red embodiment ofthe bacteria detection system, the system comprises a biological fluid processing system comprising a plurality of containers, for example, a first container for receiving and/or ting biological fluid (e.g., a “source container”), and at least a second container (e.g., as part of a biological fluid sampling device, that is also part of the ) for receiving a portion of the biological fluid, n the second container contains the detergent and bacterial growth promoter, and the glucose reading and/or measuring device, that detects the levels ofglucose in the biological fluid over the period of time. The biological fluid processing system typically includes a plurality of conduits for providing fluid communication between the containers, and may e additional elements such as, for example, one or more additional containers (e.g., for an additive solution and/or for containing processed biological fluid components) and/or a filter device (e. g., a leukocyte depletion filter device) and/or one or more vents such as a gas inlet and/or a gas outlet. lly, the biological fluid processing system also includes one or more fluid flow control devices such as clamps, transfer leg closures, check valves, and/or ble valves.

Embodiments ofthe bacteria detection system and/or the ical fluid processing system preferably comprise a detachable (or an attachable and detachable) biological fluid sampling . For example, a biological fluid processing system can be produced including the biological fluid sampling device, or the biological fluid sampling device can be attached (e.g., via sterile docking to maintain sterility) to an ng biological fluid processing system (including any cially available biological fluid processing system such as a blood bag set). A t allowing fluid communication between the first (source) container and the second container (the container of the biological fluid sampling device) can be cut (preferably by heat-sealing to in the sterility of the contents of the sampling device and the source ner) after the fluid has been passed hrough, and the bacteria can be subsequently detected.

Alternatively, or additionally, the bacteria detection system and/or the ical fluid processing system can include a biological fluid sampling device that is connected (e.g., to the first container) by a tether, preferably a flexible tether such as a plastic cord or cable.

Illustratively, the conduit described above can be cut and sealed, and the separate tether keeps the analysis chamber associated with the source ner, e.g., until the is for bacteria is completed.

Since bacteria can be detected in accordance with the invention, embodiments of the present invention can be suitable for providing blood components that can be stored for longer periods than are currently allowed by the regulations in various countries. For example, due, at least in part, to fears that platelet concentrate (PC) can be contaminated with bacteria, current U.S. ce requires that, when processed in a closed system, individual units ofPC and pooled PC be utilized within 5 days. However, since ments of the invention allow the detection of inated PC, pooled and unpooled PC can be monitored, and ifdetermined to be uncontaminated, can be used alter the 5 day limit that is currently required. Illustratively, individual units ofPC or pooled PC processed in a closed system can be transfused after, for example, 7 days of storage.

A wide variety of bacteria, including gram-positive, egative, aerobic, and bic bacteria, utilize glucose, and thus, in accordance with embodiments of the invention, a decrease in the glucose level or concentration in the biological fluid over a period oftime reflects the presence ofbacteria.

Illustratively, embodiments provide for detecting the presence ofbacteria, wherein the bacteria present can be one or more ofthe following: Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus luga'unensis, Serratia marcescens, ia liquefaciens, Yersinia enterocolitica, Klebsiella nia, Klebsiella oxytoca, Escherichia coli, Enterobacter cloacae, Enterobacter nes, Pseudomonas aeruginoisa, Eubacterium limosum; Salmonella spp., such as Salmonella enterica (formerly Salmonella aesuis); Bacillus spp. such as Bacillus cereus; Clostridium perfringens, Propionibacterium acnes, ococcus agalactiae (also known as Group B streptococcus or GBS), ococcus bovis (at least some strains now called Streptococcus gallolyticus), StreptococCus infantarius, and Streptococcus mills.

Systems and methods according to the present invention are particularly suitable for use by transfiision services, blood centers and/or blood bank personnel.

If d, once the presence of bacteria is determined in accordance with the invention, further analysis can be carried out by known techniques to identify the ular species ofbacteria present.

Each ofthe ents ofthe invention will now be described in more detail below, wherein like components have like reference numbers.

Preferably, an embodiment ofthe sampling device comprises a container having at least two ports, and at least one conduit in fluid communication with at least one of the ports.

Figure 1 illustrates a biological fluid sampling device 100 for use in an embodiment ofthe invention. The illustrated sampling device comprises a sampling device container 50 (e.g., a “sampling container”) for receiving a portion of a biological fluid, the container including an access port 10 (e.g., a “glucose sampling port”) and a able element 11 (such as an elastomeric diaphragm) g one end of the port, wherein the pierceable element includes a rable portion 12 (preferably located at or near the center ofthe element) allowing insertion of, for example, a liquid withdrawal device (such as, for example, a syringe; typically, wherein the withdrawal device further comprises a needle or nozzle attached to the syringe) or a glucose probe, while ining a seal; a biological fluid inlet port 20, and a conduit 30 in fluid communication with the port. In some embodiments, a porous membrane 13, ably, a hydrophobic microporous membrane, is located at or near the other end ofthe port. For example, after the needle or nozzle attached to the syringe punctures the diaphragm (without penetrating the membrane 13), the plunger of the syringe can be partially withdrawn in the syringe barrel, creating a vacuum and pulling biological fluid from the container and through the membrane into the barrel. Typically, the access port is made of a ent material than the container 50.

Preferably, the conduit 30 is sterile dockable, so that the device can be connected to, for example, another conduit and/or a container, via sterile g, so that a closed system can be provided. In some embodiments, e.g., as ‘shown in Figure l, the system comprises a flow control device 35, such as a one-way check valve in fluid communication with the conduit, and at least one onal t 36 (preferably, a sterile do ckable conduit) in fluid communication with the check valve. The sampling device includes a detergent and a ial growth promoter, and the illustrated sampling device includes, within the container, two s 5, 5a, each sing a detergent and a bacterial growth promoter. Preferably, as shown in Figure l, the device also includes a region suitable for applying indicia, e.g., printed or etched thereon, or for receiving a label with the indicia thereon.

If desired, the sampling device could include, e.g., the access port could further comprise, a luer connector (not shown), allowing a liquid withdrawal device such as a syringe to be connected to the sampling device for subsequent withdrawal of liquid from the ner.

Figure 1 also shows a diagrammatic glucose reading device and/or e measuring device 500.

Typically, and as illustrated in Figure 2, a bacteria detection system 1000 comprises a biological fluid sing system 300 comprising a plurality of containers, for example, a first container 51 for receiving and/or collecting biological fluid, and at least the second container 50 (as part of the ical fluid sampling device 100 shown in Figure 1, which is also part of the system) for receiving a portion of the biological fluid passed from the first container, wherein the second container contains the detergent and bacterial growth promoter, and wherein a glucose g device and/or a glucose measuring device 500 detects and/or measures the levels ofglucose in the biological fluid over the period of time.

The illustrated biological fluid processing system includes a plurality of conduits for providing fluid communication between the ners.

In some embodiments, the bacteria detection system comprises a biological fluid processing system comprising a plurality of containers, and a leukocyte depletion filter. For example, in the embodiment illustrated in Figure 3, the bacteria detection system 1000 comprises a biological fluid processing system 300 sing a plurality of containers, and a leukocyte depletion filter 250. The rated biological fluid processing system 300 ses a first container 51, e. g, for receiving pooled biological fluid (pooling manifold and containers of dual units ofPC not shown), and at least the second container 50 (as part of the biological fluid ng device 100 shown in Figure 1, which is also part of the system) for receiving a portion of the biological fluid passed fi‘om the first container, wherein the second container contains the detergent and bacterial growth promoter, and wherein a glucose reading device and/or a glucose ing device 500 detects and/or measures the levels of glucose in the biological fluid over the period of time. In accordance with the illustrated system, biological fluid is passed from first container 51 through leukocyte depletion filter 250 into third container 53, which can comprise a storage container. The illustrated biological fluid processing system includes a plurality of conduits for providing fluid communication between the containers.

The biological fluid processing system 300 illustrated in Figure 3 r comprises a vent 225 (that can comprise a gas inlet and/or a gas ) and a vent pouch 275 , for use as is known in the art. For example, pooled PC can be passed into first container 51, and the vent 225 can allow air to pass through the vent and allow PC in the conduit between the vent and the first container to flow into the container. Subsequently, air in the container 51 can be passed through the conduit and the vent, and the conduit is sealed. In those embodiments wherein the system includes a vent pouch 275, after leukocyte depleted biological fluid is passed into third container 53, air in container 53 can be passed into vent pouch, and the conduit leading to container 53 can be sealed.

While Figure 3 illustrates second container 50 (as part of the biological fluid sampling device 100) in fluid communication with first container 51 (allowing sampling before leukocyte depletion), in another embodiment (not , second container 50 (as part ofthe biological fluid sampling device 100) is in fluid ication with third ner 53 (e.g., allowing sampling after leukocyte depletion).

The ent and/or the bacterial grown promoter can be in dry form (e.g., a powder or a tablet) or in liquid form. In either form, further components, ingredients and/or additives can be included. If desired, e.g., wherein the detergent and/or the bacterial grown promoter are in dry form, for example, tablet form, further components, ingredients and/or additives can include, for e, an inert material such as one or more of the ing: maltose, mannitol, and a salt such as calcium chloride, e.g., to provide bulk and/or for ease of binding.

The detergent according to the invention significantly reduces the respiration of blood cells (platelets, red blood cells, and ytes) but has little or no effect on bacterial respiration. A preferred detergent is sulfonic polyanethol sodium (SPS).

A variety ofbacterial growth promoters are suitable for use in the invention. One preferred promoter is trypticase soy broth (TPB). Other suitable ers e, but are not limited to, broths such as lysogeny broth (LB broth), mannitol broth, M9 minimal media (that can be supplemented with, for example, one or more ofthe ing: glucose, m, and magnesium), or other broths, including supplemented broths.

The glucose level is detected in liquid. For example, a small volume ofbiological fluid can be removed from the sampling device container (via an access (glucose sampling) port, using a liquid withdrawal device, typically, comprising a syringe) and typically placed on a reagent pad or a test strip which is inserted into a glucose reading device and/or glucose measuring device, and this is repeated at least once after a suitable period of time.

Alternatively, for example, a probe can be placed in the sampling device container wherein the container is at least partially filled with biological fluid, the probe is placed in the , and a probe reading can be taken, and the probe is removed and a probe (the same or a different probe) is inserted after a suitable period oftime, and another probe reading is taken.

Alternatively, the probe can remain in the container allowing multiple and/or continuous readings. A decrease in the glucose level over a period oftime indicates ia are present.

A variety of equipment, s and/or protocols are suitable for detecting the level or concentration ofglucose in the biological fluid. Illustrative suitable devices 500 (including e reading devices and glucose ing devices) are known in the art and include cially available devices, available from, for example, LifeS can, Inc.

(Milpitas, CA; e.g., Glucometer SureStep Flexx , OneTouch® Blood Glucose Meters), Roche Diagnostics Corp. napolis, IN; e.g., ACCU-CHEK® meters), Abbott Laboratories (Abbott Park, IL; e.g., Optimum ), Nipro Diagnostics, Inc. (Fort Lauderdale, FL, e.g., TrueTrack® products), and Bayer (Terrytown, NY; e.g., the 1265 Rapidlab® Blood Gas Analyzer).

Glucose reading devices and glucose measuring devices can be set up to provide, for example, “pass” and “fail” results, e.g., wherein a glucose threshold is set up, and once a value below that old is detected, the unit of biological fluid “fails” and if a value below that old is not detected, the unit ofbiological fluid “passes.” atively, or additionally, the glucose reading devices and glucose measuring devices can be set up to measure glucose levels, wherein the levels are correlated with bacterial contamination, or non-contamination.

One or more probes, sensors, or liquid withdrawal devices can be utilized, e.g., placed in or on the container for the biological fluid. In some embodiments, the components, e.g., liquid withdrawal devices, probes and/0r sensors, are self-contained and suitable for one—time use. Embodiments of systems according to the invention can include these items pre-assembled and/or pre—attached, e.g., before biological fluid is passed into the container.

Alternatively, or additionally, one or more of these items can be assembled, ed, and/or used during or alter the passage ofbiological fluid into the container. ments ofthe invention are le for a variety of applications, and the biological fluid can be from a number of s, preferably mammals. The biological fluid can be from a subject such as a human (e.g., a donor ing a unit ofblood or a pheresis product) or an animal. In some embodiments, e.g., in some embodiments wherein biological fluid is to be administered as a transfusion product, or the biological fluid is cord blood or comprises stem cells, the method is preferably carried out while maintaining a closed system.

Embodiments ofthe method can be carried out in any suitable period oftime and at any suitable temperature. For example, a biological fluid can be collected fi'om a subject (and, if desired, processed to separate the biological fluid into one or more components) and maintained at, illustratively, room temperature, for a period ofup to about 24 hours from collection, before biological fluid is placed in contact with the detergent and bacterial growth promoter and a first level ofglucose in the fluid is measured and/or detected. Typically, biological fluid (e.g., blood) is collected and processed to provide separated components, e.g., wherein one separated component is a unit ofPC, and the unit ofPC (or pooled PC) is maintained in a first container, and a portion of the PC is passed from the first container to a second container, where it is placed in contact with the detergent and bacterial growth promoter, preferably, wherein the second container contains the detergent and the bacterial grth promoter before the biological fluid is passed into the second container. After a suitable period of time, e.g., after at least about 4 hours (for e, a biological fluid such as PC is placed in contact with the ent and bacterial growth promoter within about 24 hours of collection of blood, and the suitable period oftime is an additional 4 hours), the second glucose level is measured and/or detected. ably, in those embodiments wherein the ical fluid is a platelet-containing fluid (e.g., pooled or single unit PC), the platelet-containing fluid in contact with the detergent and the bacterial growth promoter is maintained, for this suitable period of time, at a ature greater than room temperature, e.g., it is ined at a temperature of about 35 0C.

The level or concentration of glucose in the biological fluid can be measured and/or ed over any suitable period oftime. Typically, the period oftime is in the range of from about 4 to about 15 hours, more preferably, about 5 to about 13 hours, between measuring and/or detecting the first level, and measuring and/or detecting the second level. ably, in some ofthose embodiments wherein the sampling device is detached from the source container, e.g., the source container is no longer in fluid ication with the sampling ner, the source container can be processed differently than the sampling device. For example, afier a t interposed between the source container and the sampling device is sealed and cut, the sampling device can be processed in conditions more ive to rapid microorganism growth (e.g., stored at a higher than ambient temperature, e.g., a temperature of about 35 to about 37° C), and the source container can be processed in a more conventional manner (e.g., stored at an ambient temperature of about 22° C).

The following definitions are used in accordance with the invention.

Biological Fluid. A biological fluid includes any treated or untreated fluid associated with living organisms, particularly blood, including whole blood, warm or cold blood, cord blood, and stored or fresh blood; treated blood, such as blood diluted with at least one logical solution, including but not limited to saline, nutrient, additive and/or anticoagulant solutions; blood components, such as platelet concentrate (PC), platelet-rich plasma (PRP), platelet-poor plasma (PPP), platelet-free plasma, plasma, fresh fiozen plasma (FFP), components obtained fiom plasma, packed red cells (PRC), transition zone material or buffy coat (BC); blood products derived fi‘om-blood or a blood component or derived flom bone ; stem cells; red cells separated firom plasma and resuspended in a physiological solution or a cryoprotective fluid; and platelets separated from plasma and resuspended in a physiological on or a cryoprotective fluid. A biological fluid also includes a cell culture, and a physiological solution comprising a bone marrow aspirate. The biological fluid may have been treated to remove some ofthe leukocytes before being sed according to the ion. As used herein, blood product or biological fluid refers to the components described above, and to similar blood products or biological fluids obtained by other means and with similar properties.

A "uni " is the quantity of biological fluid from a donor or derived from one unit ofwhole blood. It may also refer to the quantity drawn during a single donation. Typically, the volume of a unit varies, the amount differing from patient to patient and from donation to donation. Multiple units of some blood components, particularly ets and buffy coat, may be pooled or combined, typically by combining four or more units.

As used herein, the term “closed” refers to a system that allows the collection and processing (and, if desired, the manipulation, e.g., tion ofportions, separation into components, filtration, storage, and vation) of biological fluid, e.g., donor blood, blood s, and/or blood components, without the need to compromise the sterile integrity of the system. A closed system can be as originally made, or result from the connection of system components using what are known as “sterile docking” devices. Illustrative sterile docking devices are disclosed in, for example, U.S. Patents 4,507,119, 4,737,214, and 4,91 3 ,756.

If desired, embodiments ofthe invention can include automated tracking and/or ted detection protocols and equipment. For example, one or more containers and the ng device can include indicia (e.g., bar coding labels) with information such as one or more ofthe following: the (s) ofthe biological fluid, blood type, additive(s) utilized, an indication r a ed level of the glucose was reached, incubation temperature, and this information can be d, combined with the measured or detected results, and provided in whatever format is suitable, e.g., ted (in machine readable form if desired) on at least one of the sampling device, source container, and the storage container, and/or as a print-out. This information can be added to the electronic records/database of the user or user’s institution, e.g., locally or via a web-based version.

The biological fluid sampling container preferably ses a e container, typically made from materials such as those conventionally used in producing blood bags (e. g., collection bags and/or satellite bags). An embodiment of a biological fluid processing system according to the invention typically comprises a plurality of conduits and containers, preferably flexible containers such as blood bags (e.g., collection bags, ite bags, and/or e bags), and vent (air or gas) pouches or bags. In one embodiment, a system according to the invention comprises a closed system. A wide variety of suitable containers and conduits are known in the art. For example, blood tion and satellite bags, and conduits, can be made fiom plasticized polyvinyl chloride. Bags and/0r conduits can also be made from, for example, ethylene butyl acrylate copolymer (EBAC) resin, ethylene methyl acrylate copolymer (EMAC) resin, plasticized ultra—high—molecular weight PVC resin, and ethylene vinyl acetate (EVA). The bags and/or conduits can also be formed firom, for example, polyolefin, polyurethane, polyester, and polycarbonate.

Suitable access ports, pierceable agms, flow control s (including clamps, transfer leg closures, check valves, and rotatable valves), and pooling manifolds, are also known in the art and are commercially available.

In those embodiment including a leukocyte depletion filter, a variety of leukocyte depletion filters are suitable for use in the invention, for example, as bed in US. Patents 4,880,548, 4,925,572, 5,152,905, and 6,074,869. In those embodiments including a vent such as a gas inlet and/or a gas outlet (e.g., sing a housing and at least one vent element comprising a porous membrane disposed in the housing), a variety ofmaterials are suitable for use as vent elements. Suitable ts, including hilic orous membranes and hydrophobic porous membranes, and vents, are disclosed in, for example, US. Patent Nos. 5,126,054 and 5,451,321. ably, when used in accordance with a closed system, the gas inlet and/or gas outlet prevents the passage ofbacteria therethrough, e.g., the gas inlet and gas outlet include a vent element having a bacterial ng pore rating.

The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.

EXAMPLE 1 This example demonstrates that glucose measurement can be used to detect the presence of c and anaerobic bacteria.

A sampling device 100 as generally shown in Figure l is obtained. The sampling device container 50, which has a volume of about 10 mL, contains 2 tablets, each tablet including 1.75 mg SPS, TSB, calcium chloride, and cturing processing agents.

Flexible tubing 30 and 36 are each about 2 inches in length.

Whole blood is collected into collection sets including anticoagulant, and processed (including filtration) to provide units of leukocyte-depleted platelet concentrate (PC) in individual containers. After 24 hours, the PC units are inoculated at target inoculums of 1-10 CFU/mL or 100-250 CFU/ML, with the ing bacteria. —_—_I __I— __I—— __I_ _'—_I_— __I_- l—_—_ ___I—— __I—— __I—— After e docking the container ofPC to the sampling device, approximately -6 mL of each inoculated unit is placed in a sampling device as generally shown in Figure 1, using non-gas permeable containers for the anaerobic ia and gas permeable containers for the aerobic bacteria, and samples are taken to measure the percent oxygen and glucose levels. The respective sampling devices are incubated under anaerobic and aerobic ions at 35 °C for 18 and 24 hours with agitation, and samples are taken to measure the percent oxygen and glucose levels at 18 and 24 hours. The glucose levels are measured using a Bayer 1265 Rapidlab® Blood Gas Analyzer (Terrytown, NY) operated in accordance with the cturer’s instructions.

Additionally, samples are taken 2 hours after inoculation, and the percent oxygen and glucose levels are measured.

Units ofnon-inoculated PC are used as controls.

The glucose levels at sample times 0 hours and 2 hours for inoculated units are in the range from about 12 to 28 mmol/L, and the glucose levels at sample times 18 hours and 24 hours are about 0 to about 3 mmol/L.

The e levels at sample times 0 hours and 2 hours for the controls are in the range from about 12 to 28 mmol/L, and the glucose levels remain at approximately those ranges at sample times 18 hours and 24 hours.

This e demonstrates that the glucose level decreases over time in the inoculated units, reflecting the growth of aerobic and anaerobic bacteria.

EXAMPLE 2 This example demonstrates that glucose measurement can be used to detect the presence of aerobic and anaerobic bacteria over varying sample device incubation times of 6-24 hours.

Whole blood is collected into collection sets including anticoagulant, and processed (including filtration) to provide units ofleukocyte-depleted platelet concentrate (PC) in individual containers. After 24 hours, the PC units are ated at target inoculums of 1-10 CFU/mL with the following bacteria.

Aerobic ia Arcc# .Historlcalc'oun't CFUImL 27853 Salmonella choleraesuis 8326 2 x 10E9 43862 9x103; Klebsiella pneumoniae 8045 Staphylococcus aureus 27217 Sta - h lococcus e . lclermidls 49134 3x10E8 Stre . (ococci a . alacllae 12927 Streptococci bovls 3331 13x10E8 streptococci mitis 1 x10E7 After an additional 24 hours, the containers ofPC are sterile docked to ng devices.

Afier sterile docking, approximately 5-6 mL of each ated unit is placed in a sampling device as generally shown in Figure 1 (including 2 tablets, each tablet including SPS, TSB, calcium chloride, and manufacturing processing agents), using s permeable containers for the bic bacteria and gas permeable containers for the aerobic bacteria, and samples are taken to measure the percent oxygen and glucose . The respective sampling devices are ted under anaerobic and aerobic conditions at 35 °C for 6, 9, 12, and 24 hours with ion, and samples are taken to measure the pH, percent oxygen and glucose levels at 6, 9, 12, and 24 hours. The glucose levels are measured using a Bayer 1265 Rapidlab® Blood Gas Analyzer (Terrytown, NY) operated in accordance with the manufacturer’s instructions.

Units of non-inoculated PC are used as controls.

The glucose levels for the PC (inoculated and controls) when placed in the sampling devices are about 26 mmol/L. The glucose levels ofthe inoculated units in the sampling devices at sample times 6 hours, 9 hours, and 12 hours are about 13 mmol/L, 4.5 mmol/L and 4.2 mmol/L, respectively, and the glucose levels for the controls at these sample times remain about 26 mmol/L.

This example demonstrates that the glucose level measurably decreases in 6, 9, and 12 hours of incubation in a ng device, reflecting the growth of c and anaerobic bacteria.

All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and cally indicated to be incorporated by reference and were set forth in its entirety herein.

The use ofthe terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the , unless otherwise indicated herein or clearly dicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not d to,”) unless otherwise noted. Recitation ofranges ofvalues herein are merely intended to serve as a shorthand method ofreferring individually to each te value g within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all es, or exemplary language (e. g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the ion unless otherwise claimed. No ge in the specification should be ued as indicating any non-claimed element as essential to the practice of the invention. [0078a] The term “comprising” as used in this specification means “consisting at least in part of’. When interpreting each statement in this specification that includes the term “comprising”, features other than that or those prefaced by the term may also be present.

Related terms such as “comprise” and “comprises” are to be interpreted in the same manner.

Preferred embodiments of this ion are described herein, including the best mode known to the inventors for ng out the invention. Variations ofthose preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the ors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents ofthe subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination ofthe above-described ts in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such s of ation, in any jurisdiction, are prior art, or form part ofthe common general dge in the art.

In the description in this specification reference may be made to t matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application.

Claims (10)

WHAT WE CLAIM IS:

1. A method for detecting bacteria in a ical fluid, the method comprising: (a) placing a biological fluid, the biological fluid ly containing bacteria, in a container, wherein the container includes (i) a detergent for reducing the respiration ofblood cells, and (ii) a ial growth promoter; and, (b) measuring and/or detecting the level of glucose in the biological fluid in the container over a period of time, n a decrease in the level of glucose over the period oftime indicates the presence of bacteria.

2. The method of claim 1, wherein the biological fluid comprises a et—containing fluid.

3. The method of claim 1, wherein the biological fluid comprises a stem cell-containing fluid.

4. The method of claim 1, wherein the biological fluid comprises a cell culture.

5. The method of any one of claims 1-4, comprising measuring and/or detecting a first level of e in the container, and, within about 4 to about 15 hours ofmeasuring and/or ing the first level, measuring and/or detecting a second level of glucose in the container.

6. The method of any one of claims 1—5, comprising obtaining a biological fluid from a subject, and, within about 24 hours or less of obtaining the ical fluid fiom the subject, passing a portion of the biological fluid into the container where the portion of biological fluid is placed in contact with the detergent and the bacterial growth promoter.

7. The method of any one of claims 1—6, wherein the biological fluid comprises a leukocyte—depleted fluid.

8. A system for detecting bacteria in biological fluid when used in a method of claim 1, said system, comprising: (a) a biological fluid sampling device comprising a container suitable for containing a biological fluid, the container comprising a glucose access port, wherein the container contains (i) an effective amount ofa detergent for reducing the respiration ofblood cells, and (ii) an effective amount of a bacterial growth promoter; and, (b) a glucose measuring device and/or glucose reading device, wherein the device is suitable for, over a period of time, measuring or ing a first level of glucose in the biological fluid, and a second level of glucose in the biological fluid, wherein a decrease in the level of glucose over the period oftime indicates the presence ofbacteria.

9. A method as claimed in claim 1, substantially as herein described with reference to any example thereof and with or without reference to the anying drawings.

10. A system as claimed in claim 8, ntially as herein described with nce to any e thereof and with or without reference to the accompanying drawings. FIG.